Live
Clinical OMICsReporter’s Notebook: Are One-Shot Gene Editors Ready to Tackle Chronic Illness?FierceBiotechASCO: Telix tees up pivotal test for Pluvicto challenger while eyeing ‘white space’ on radiopharma canvasFierceBiotechAt ASCO 2026, a ‘paradigm shift’ for a rare gut cancer loomsBioPharma DiveRallyBio tries again for reverse merger, this time with AvenzoEndpoints NewsThe cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that wayEndpoints NewsEpigenetic editing shows promise against chronic hep B infectionsFierceBiotechASCO, Ryght AI team up for breast cancer trial site selectionClinical OMICsSMArT Platform Improves Safety and Efficiency of CRISPR Editing in HSPCsClinical OMICsPancreatic Cancer Drug Doubles Survival While Reducing Side EffectsEndpoints NewsShionogi wins US approval for first pill to prevent Covid following exposureBioWorldAppointments and advancements for June 1, 2026BioWorldFinancings for June 1, 2026
BioWorld Apr 17, 2026

PROTAC CDK4/6 degraders disclosed in K2 Medicines patent

PROTAC CDK4/6 degraders disclosed in K2 Medicines patent

Original
Body unavailable. Use the original source.